Majdolen Istaiti

Upgrading the evidence for the use of ambroxol in Gaucher disease and <scp>GBA</scp> related Parkinson: Investigator initiated registry based on real life data

Majdolen Istaiti, Shoshana Revel‐Vilk, Michal Becker‐Cohen et al. · American Journal of Hematology · 2021 · 48 citations · Full text

Ambroxol Hydrochloride, Neurological Disorder, Pathology +20

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?

Tama Dinur, Peter Bauer, Christian Beetz et al. · International Journal of Molecular Sciences · 2022 · 37 citations · Full text

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease

Tama Dinur, Majdolen Istaiti, Dafna Frydman et al. · Orphanet Journal of Rare Diseases · 2020 · 25 citations · Full text

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations

Tama Dinur, Ulrike Grittner, Shoshana Revel‐Vilk et al. · International Journal of Molecular Sciences · 2021 · 23 citations · Full text

Type 1, Translational Medicine, Autoimmune Disease +12

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy

Majdolen Istaiti, Michal Becker‐Cohen, Tama Dinur et al. · Journal of Clinical Medicine · 2022 · 13 citations · Full text